- NCIt
- C227218
Loading cancer entity…
Loading cancer entity…
Clinical trials
6 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06253871 | A Phase 1/1b Study of IAM1363 in HER2 Cancers | recruiting | Phase 1 | 383 | Iambic Therapeutics, IncINDUSTRY | 8 | Sep 9, 2026 | clinicaltrials |
| NCT07384377 | JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan | not yet recruiting | Phase 3 | 123 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Feb 3, 2026 | clinicaltrials |
| NCT05985707 | KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma | not yet recruiting | Phase 2 | 80 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 21, 2023 | clinicaltrials |
Data updated 21 days agoSource updated Sep 9, 2026source: clinicaltrials